Related Experiment Video
Updated: Dec 9, 2025
09:51
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
Published on: December 4, 2023
1.5K
Gallbladder neuroendocrine carcinoma: A single center experience
Hongwu Chu1,2, Chengwu Zhang1, Ying Shi3
1Hepatobiliary and Pancreatic Surgery.
Medicine
|September 9, 2020
Summary
Gallbladder neuroendocrine carcinoma (GB-NEC) is rare. Surgical resection and chemotherapy may prolong survival in advanced cases. Elevated cancer antigen 125 (CA-125) may indicate a poor prognosis.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Gallbladder neuroendocrine carcinoma (GB-NEC) is a rare and heterogeneous malignancy.
- Limited clinical data exists for GB-NEC, necessitating further investigation into its characteristics and management.
Purpose of the Study:
- To analyze the clinical and pathological features of GB-NEC.
- To evaluate treatment outcomes and prognostic factors for GB-NEC patients.
Main Methods:
- Retrospective analysis of 7 GB-NEC patients treated between January 2011 and October 2019.
- Clinical data, imaging (CT), pathological findings, treatment modalities, and survival outcomes were reviewed.
Main Results:
- The median age was 58 years; right upper quadrant discomfort was the primary symptom.
- Contrast-enhanced CT showed mucosal enhancement in most cases; elevated cancer antigen 125 (CA-125) correlated with liver metastases and poor prognosis.
- Surgical resection, including laparoscopic procedures, was feasible; chemotherapy combined with surgery improved survival, with a median survival of 4.6 months.
Conclusions:
- Surgical resection and chemotherapy are potential treatment strategies for advanced GB-NEC, offering survival benefits.
- Elevated CA-125 levels may serve as a valuable prognostic marker for GB-NEC, warranting further research.
